Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, u... Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform. Show more
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.049 | 7 | 0.7 | 0.749 | 0.6805 | 118509 | 0.70293138 | CS |
4 | -0.011 | -1.44736842105 | 0.76 | 0.85 | 0.6756 | 158507 | 0.75382955 | CS |
12 | -0.065 | -7.98525798526 | 0.814 | 0.8586 | 0.5084 | 166807 | 0.69871787 | CS |
26 | -4.271 | -85.0796812749 | 5.02 | 6.84 | 0.5084 | 456194 | 1.45795811 | CS |
52 | -0.1434 | -16.069027342 | 0.8924 | 9.3722 | 0.5084 | 511771 | 2.21338974 | CS |
156 | -13.901 | -94.8873720137 | 14.65 | 17.4899 | 0.5084 | 252181 | 2.44080054 | CS |
260 | -19.371 | -96.2773359841 | 20.12 | 26.75 | 0.5084 | 226454 | 3.9486681 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.